Phase 1 Clinical Study of Cyclophilin B Peptide Vaccine for Patients With Lung Cancer

Rumi Gohara, Nobue Imai, Toru Rikimaru, Akira Yamada, Naoya Hida, Masao Ichiki, Mayumi Kawamoto, Kazuko Matsunaga, Junko Ashihara, Sayoko Yano, Mayumi Tamura, Shinya Ohkouchi, Hideaki Yamana, Kotaro Oizumi, Kyogo Itoh

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)


Cyclophilin B (CypB) possesses two antigenic epitopes (CypB84-92 and CypB91-99) recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes (CTLs). To determine the safety of CypB-derived peptides and its ability to generate antitumor immune responses, patients with advanced lung cancer received subcutaneous vaccinations of these peptides or their modified peptides. All 16 patients were vaccinated with CypB91-99 or its modified peptide, whereas only two patients were vaccinated with the modified CypB84-92, as immediate-type hypersensitivity to CypB84-92 or its modified peptide was observed in the remaining patients. No severe adverse events were associated with the vaccination. No significant increase in cellular responses to either peptides or tumor cells was observed in the postvaccination PBMCs by the conventional CTL assays in any patients tested. These results suggest that the vaccination of CypB91-99 peptide was safe, but failed to induce objective immune responses at this regimen.

Original languageEnglish
Pages (from-to)439-444
Number of pages6
JournalJournal of Immunotherapy
Issue number5
Publication statusPublished - 2002


  • Cytotoxic T lymphocyte-peptides
  • Immunotherapy
  • Lung cancer
  • Phase 1 study


Dive into the research topics of 'Phase 1 Clinical Study of Cyclophilin B Peptide Vaccine for Patients With Lung Cancer'. Together they form a unique fingerprint.

Cite this